NASDAQ: PROKProkidney Corp Stock
$2.57+0.11 (+4.47%)
Updated Dec 4, 2025
PROK Price
$2.57
Fair Value Price
$0.98
Market Cap
$773.14M
52 Week Low
$0.46
52 Week High
$7.13
P/E
-4.67x
P/B
-0.77x
P/S
439.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$744.00k
Earnings
-$71.03M
Gross Margin
100%
Operating Margin
-9,049.33%
Profit Margin
-9,547.4%
Debt to Equity
-0.03
Operating Cash Flow
-$112M
Beta
1.29
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PROK Overview
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PROK's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PROK
Ranked#260 of 485
Ranked#260 of 485
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.86 | A | |
| $331.40 | A | |
| $100.46 | A |
Be the first to know about important PROK news, forecast changes, insider trades & much more!
PROK News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PROK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PROK ($2.57) is overvalued by 161.67% relative to our estimate of its Fair Value price of $0.98 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PROK ($2.57) is not significantly undervalued (161.67%) relative to our estimate of its Fair Value price of $0.98 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PROK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PROK due diligence checks available for Premium users.
Valuation
PROK fair value
Fair Value of PROK stock based on Discounted Cash Flow (DCF)
Price
$2.57
Fair Value
$0.98
Overvalued by
161.67%
PROK ($2.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PROK ($2.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PROK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PROK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.67x
Industry
192.46x
Market
46.53x
PROK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.77x
Industry
5.31x
PROK's financial health
Profit margin
Revenue
$217.0k
Net Income
-$16.5M
Profit Margin
-7,589.4%
PROK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PROK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$351.6M
Liabilities
$33.3M
Debt to equity
-0.03
PROK's short-term assets ($299.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PROK's short-term assets ($299.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PROK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PROK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.6M
Investing
$29.0M
Financing
$8.0M
PROK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PROK vs Biotech Stocks
Prokidney Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.